Absolute Oral Bioavailability of Remimazolam

Phase 1 Completed 14 enrolled Paion UK Ltd. PRA Health Sciences · collab

RandomizedCrossoverOpen-labelOther

Summary

A randomized, open-label, single-dose, 2-way crossover study to compare the relative bioavailability of orally administered remimazolam to an intravenous formulation in healthy volunteers

Timeline

Start: 2015-11-03
Primary completion: 2015-11-20
Completion: 2015-11-20

Publications

Pesic M, Stohr T, Ossig J, Borkett K, Donsbach M, Dao VA, Webster L, Schippers F. Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials. Drugs R D. 2020 Sep;20(3):267-277. doi: 10.1007/s40268-020-00317-0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Remimazolam	Small molecule	0.025 mg/kg	Intravenous
Subject	Remimazolam	Small molecule	0.14 mg/kg	Intravenous

Indications

No indication recorded.